

# Global Tyrosine Kinase JAK Inhibitors Market Study 2015-2025, by Segment (Tofacitinib, Ruxolitinib, Baricitinib), by Market (Rheumatoid Arthritis (RA), Polycythemia Vera (PCV)Ruxolitinib, Myelofibrosis (MF)), by Company (Pfizer, Incyte, Novartis)

https://marketpublishers.com/r/GB71D0B59D4EN.html

Date: October 2018 Pages: 69 Price: US\$ 1,800.00 (Single User License) ID: GB71D0B59D4EN

# **Abstracts**

Snapshot

Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway.

The global Tyrosine Kinase JAK Inhibitors market will reach xxx Million USD in 2018 and with a CAGR if xx% between 2019-2025.

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):

Tofacitinib

Ruxolitinib

Baricitinib

Demand Coverage (Market Size & Forecast, Consumer Distribution):

Rheumatoid Arthritis (RA)

Global Tyrosine Kinase JAK Inhibitors Market Study 2015-2025, by Segment (Tofacitinib, Ruxolitinib, Baricitini...



Polycythemia	Vera	(PCV)
--------------	------	-------

Myelofibrosis (MF)

Others

Company Coverage (Sales data, Main Products & Services etc.):

Pfizer Incyte Novartis Eli Lilly Gilead Sanofi Galapagos AbbVie Vertex Teva Astellas Pharma Celgene **CTI BioPharma** 

Major Region Market

Global Tyrosine Kinase JAK Inhibitors Market Study 2015-2025, by Segment (Tofacitinib, Ruxolitinib, Baricitini...



North America

Europe

Asia-Pacific

South America

Middle East & Africa

Global Tyrosine Kinase JAK Inhibitors Market Study 2015-2025, by Segment (Tofacitinib, Ruxolitinib, Baricitini...



# Contents

### **1 INDUSTRY OVERVIEW**

- 1.1 Tyrosine Kinase JAK Inhibitors Industry
- 1.1.1 Overview
- 1.1.2 Products of Major Companies
- 1.2 Market Segment
- 1.2.1 Industry Chain
- 1.2.2 Consumer Distribution
- 1.3 Price & Cost Overview

# 2 TYROSINE KINASE JAK INHIBITORS MARKET BY TYPE

- 2.1 By Type
  - 2.1.1 Tofacitinib
  - 2.1.2 Ruxolitinib
  - 2.1.3 Baricitinib
- 2.2 Market Size by Type
- 2.3 Market Forecast by Type

### **3 GLOBAL MARKET DEMAND**

- 3.1 Segment Overview
  - 3.1.1 Rheumatoid Arthritis (RA)
  - 3.1.2 Polycythemia Vera (PCV)
  - 3.1.3 Myelofibrosis (MF)
  - 3.1.4 Others
- 3.2 Market Size by Demand
- 3.3 Market Forecast by Demand

# 4 MAJOR REGION MARKET

- 4.1 Global Market Overview
  - 4.1.1 Market Size & Growth
  - 4.1.2 Market Forecast
- 4.2 Major Region
  - 4.2.1 Market Size & Growth
  - 4.2.2 Market Forecast



#### **5 MAJOR COMPANIES LIST**

5.1 Pfizer (Company Profile, Sales Data etc.)
5.2 Incyte (Company Profile, Sales Data etc.)
5.3 Novartis (Company Profile, Sales Data etc.)
5.4 Eli Lilly (Company Profile, Sales Data etc.)
5.5 Gilead (Company Profile, Sales Data etc.)
5.6 Sanofi (Company Profile, Sales Data etc.)
5.7 Galapagos (Company Profile, Sales Data etc.)
5.8 AbbVie (Company Profile, Sales Data etc.)
5.9 Vertex (Company Profile, Sales Data etc.)
5.10 Teva (Company Profile, Sales Data etc.)
5.11 Astellas Pharma (Company Profile, Sales Data etc.)
5.12 Celgene (Company Profile, Sales Data etc.)
5.13 CTI BioPharma (Company Profile, Sales Data etc.)

#### **6 CONCLUSION**



# **List Of Tables**

# LIST OF TABLES

Table GLOBAL TYROSINE KINASE JAK INHIBITORS MARKET 2015-2018, BY TYPE, IN USD MILLION Table Global Tyrosine Kinase JAK Inhibitors Market 2015-2018, by Type, in Volume Table Global Tyrosine Kinase JAK Inhibitors Market Forecast 2019-2025, by Type, in **USD** Million Table Global Tyrosine Kinase JAK Inhibitors Market Forecast 2019-2025, by Type, in Volume Table Pfizer Overview List Table Tyrosine Kinase JAK Inhibitors Business Operation of Pfizer (Sales Revenue, Sales Volume, Price, Cost, Gross Margin) Table Incyte Overview List Table Tyrosine Kinase JAK Inhibitors Business Operation of Incyte (Sales Revenue, Sales Volume, Price, Cost, Gross Margin) **Table Novartis Overview List** Table Tyrosine Kinase JAK Inhibitors Business Operation of Novartis (Sales Revenue, Sales Volume, Price, Cost, Gross Margin) Table Eli Lilly Overview List Table Tyrosine Kinase JAK Inhibitors Business Operation of Eli Lilly (Sales Revenue, Sales Volume, Price, Cost, Gross Margin) Table Gilead Overview List Table Tyrosine Kinase JAK Inhibitors Business Operation of Gilead (Sales Revenue, Sales Volume, Price, Cost, Gross Margin) Table Sanofi Overview List Table Tyrosine Kinase JAK Inhibitors Business Operation of Sanofi (Sales Revenue, Sales Volume, Price, Cost, Gross Margin) Table Galapagos Overview List Table Tyrosine Kinase JAK Inhibitors Business Operation of Galapagos (Sales Revenue, Sales Volume, Price, Cost, Gross Margin) Table AbbVie Overview List Table Tyrosine Kinase JAK Inhibitors Business Operation of AbbVie (Sales Revenue, Sales Volume, Price, Cost, Gross Margin) **Table Vertex Overview List** Table Tyrosine Kinase JAK Inhibitors Business Operation of Vertex (Sales Revenue, Sales Volume, Price, Cost, Gross Margin) Table Teva Overview List



Table Tyrosine Kinase JAK Inhibitors Business Operation of Teva (Sales Revenue,

Sales Volume, Price, Cost, Gross Margin)

Table Astellas Pharma Overview List

Table Tyrosine Kinase JAK Inhibitors Business Operation of Astellas Pharma (Sales

Revenue, Sales Volume, Price, Cost, Gross Margin)

Table Celgene Overview List

Table Tyrosine Kinase JAK Inhibitors Business Operation of Celgene (Sales Revenue,

Sales Volume, Price, Cost, Gross Margin)

Table CTI BioPharma Overview List

Table Tyrosine Kinase JAK Inhibitors Business Operation of CTI BioPharma (Sales

Revenue, Sales Volume, Price, Cost, Gross Margin)



# **List Of Figures**

### LIST OF FIGURES

Figure Global Tyrosine Kinase JAK Inhibitors Market Growth 2015-2018, by Type, in USD Million

Figure Global Tyrosine Kinase JAK Inhibitors Market Growth 2015-2018, by Type, in Volume



# I would like to order

Product name: Global Tyrosine Kinase JAK Inhibitors Market Study 2015-2025, by Segment (Tofacitinib, Ruxolitinib, Baricitinib), by Market (Rheumatoid Arthritis (RA), Polycythemia Vera (PCV)Ruxolitinib, Myelofibrosis (MF)), by Company (Pfizer, Incyte, Novartis)

Product link: https://marketpublishers.com/r/GB71D0B59D4EN.html

Price: US\$ 1,800.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

# Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/GB71D0B59D4EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970